Roche Withdraws Cancer Drug Lunsumio From Swiss Market
Roche has removed its cancer drug Lunsumio from the Swiss market following failed talks with the Federal Office of Public Health (FOPH), denying patients access to the treatment that had been the first drug to benefit from Switzerland's new 'early access' procedure. Roche sought to halt advance payments for Lunsumio and transition to full reimbursement, citing positive patient outcomes. However, the FOPH refused, arguing that individual doctor experiences cannot replace evidence-based clinical trials. Experts suggest Roche's decision may be a message to Swiss authorities or a response to US President Donald Trump's pressure on European drug prices. Lunsumio, expected to achieve peak annual sales of $1-2 billion, is currently undergoing further tests in combination with other drugs and in an easier to administer formulation. Roche's withdrawal of Lunsumio risks undermining future negotiations and could encourage other drugmakers to follow suit, potentially holding pricing authorities to ransom. Despite the setback, the FOPH remains hopeful for a solution with Roche, and Swissmedic has extended Lunsumio's temporary authorisation until 2027. Roche's decision to withdraw Lunsumio from the Swiss market highlights the complexities of drug pricing negotiations. While Roche argues for full reimbursement based on positive patient outcomes, the FOPH maintains the need for evidence-based clinical trials. The future of Lunsumio in Switzerland remains uncertain, with both parties eager to find a resolution.
Read also:
- Vaccinations Explained: An Overview of Immunization Processes
- Health care professionals targeted in a shooting incidents, a pattern of hostile actions against health workers continues to unfold, with many observing this trend as unremarkable.
- Flu Season: Prioritize Employee Health With Vaccinations
- Brazil's Healthcare Sector Hit by Major Cyberattack: KillSec Exposes 94,818 Sensitive Files
